secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001140361-23-023200
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences receives Nasdaq delisting notice for bid price and equity non-compliance; plans to appeal
--------------------------------------------------------------------------------

- Nasdaq notified Catalyst on May 2, 2023 that it failed to regain compliance with the $1.00 minimum bid price rule and is ineligible for a second 180-day period.
- Company also remains deficient on Nasdaq's $2.5M minimum stockholders' equity requirement (Listing Rule 5550(b)(1)), an additional delisting basis.
- Catalyst plans to timely request a hearing before the Nasdaq Hearings Panel to stay suspension of its common stock pending the process.
- Company believes completion of the pending Business Combination Transaction with GNI Group entities and a reverse stock split will allow the combined company to meet initial listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123023200/0001140361-23-023200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123023200/brhc20052574_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-023200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer